[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483279":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":104,"collaborators":7,"id":106,"slug":107,"hasResults":108,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":7,"eligibilityCriteria":112,"healthyVolunteers":108,"sex":113,"minAge":114,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":115,"phases":7,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":33,"whyStopped":7,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Agenus Inc.","INDUSTRY",null,[9,15],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Balstilimab","An anti-programmed death 1 (PD-1) monoclonal antibody.",[14],"AGEN2034",{"type":10,"name":16,"description":17,"armGroupLabels":7,"otherNames":18},"Zalifrelimab","An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.",[19],"AGEN1884",[21],{"name":22,"affiliation":5,"role":23},"Medical Director","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":7,"email":29},"Agenus, Inc.","CONTACT","781-674-4265","clinicaltrialinfo@Agenusbio.com",[31,45,55,65,74,84,94],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":7},"University of Alabama at Birmingham","AVAILABLE","Birmingham","Alabama","35249","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-86.80249,33.52066,{"lat":43,"lon":42},{"facility":46,"status":33,"city":47,"state":48,"zip":49,"country":37,"countryCode":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":7},"Arizona Oncology Associates","Tucson","Arizona","85711",{"type":40,"coordinates":51},[52,53],-110.92648,32.22174,{"lat":53,"lon":52},{"facility":56,"status":33,"city":57,"state":58,"zip":59,"country":37,"countryCode":38,"cosmosGeoPoint":60,"geoPoint":64,"contacts":7},"Hoag Gynecologic Oncology","Newport Beach","California","92663",{"type":40,"coordinates":61},[62,63],-117.92895,33.61891,{"lat":63,"lon":62},{"facility":66,"status":33,"city":67,"state":58,"zip":68,"country":37,"countryCode":38,"cosmosGeoPoint":69,"geoPoint":73,"contacts":7},"University of California, San Francisco Medical Center","San Francisco","94158",{"type":40,"coordinates":70},[71,72],-122.41942,37.77493,{"lat":72,"lon":71},{"facility":75,"status":33,"city":76,"state":77,"zip":78,"country":37,"countryCode":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":7},"The Ohio State University Wexner Medical Center","Columbus","Ohio","43212",{"type":40,"coordinates":80},[81,82],-82.99879,39.96118,{"lat":82,"lon":81},{"facility":85,"status":33,"city":86,"state":87,"zip":88,"country":37,"countryCode":38,"cosmosGeoPoint":89,"geoPoint":93,"contacts":7},"Women & Infants Hospital of Rhode Island","Providence","Rhode Island","02905",{"type":40,"coordinates":90},[91,92],-71.41283,41.82399,{"lat":92,"lon":91},{"facility":95,"status":33,"city":96,"state":97,"zip":98,"country":37,"countryCode":38,"cosmosGeoPoint":99,"geoPoint":103,"contacts":7},"Texas Oncology","Flower Mound","Texas","75028",{"type":40,"coordinates":100},[101,102],-97.09696,33.01457,{"lat":102,"lon":101},{"type":105,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100483279","expanded-access-for-cancer-treatment-with-balstilimab-agen2034-and-zalifrelimab-agen1884-100483279",false,"NCT05572970","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)","Expanded Access for Cancer Treatment With Balstilimab (AGEN2034), Either as Monotherapy, or as Used in Combination With Zalifrelimab (AGEN1884)","Inclusion Criteria:\n\n* Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","EXPANDED_ACCESS","This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and\u002For wish to continue treatment, and who are eligible for treatment under this expanded access study.",[118],"Cancer",[11,14,16,19,120],"Monotherapy","2026-05-05",{"date":123,"type":124},"2026-05-06","ACTUAL",{"name":5,"class":6},7]